Verve Therapeutics: Exciting Science And A Rich Valuation

Nov. 10, 2022 3:39 AM ETVerve Therapeutics, Inc. (VERV)2 Comments
Sage Advisors profile picture
Sage Advisors


  • The science is as exciting as it gets - precision gene editing!
  • Verve Therapeutics is working to provide new alternatives for the treatment of cardiovascular disease (CVD).
  • While the science is exciting and the market opportunity very significant, the valuation may not reflect the considerable risks of developing a new technology and the long path to approval.
  • A recent clinical hold is a setback that may refocus investors on the considerable risks of pioneering a truly novel treatment.

Treatment and Adjustment of DNA



VERVE-101 is an in vivo liver directed CRISPR base editing treatment for patients with heterozygous familial hypercholesterolemia. These patients have one mutant allele in the LDLR gene, which results in high LDL levels in the blood. Longer term, the condition results in

This article was written by

Sage Advisors profile picture
M.A. Science. I use my science background, the knowledge acquired while working for a major pharmaceutical company and access to scientists with domain specific knowledge to find the best opportunities in biotech.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This in not a recommendation to buy or sell any security. I am not a financial advisor and readers should consult their own financial advisor fr advice and suitability.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.